Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users
Status:
Completed
Trial end date:
2019-06-05
Target enrollment:
Participant gender:
Summary
The etonogestrel (ENG) subdermal contraceptive implant (ENG implant) is a highly effective
method of preventing pregnancy, but it has bleeding side effects that make it unappealing for
many women. The only study to demonstrate a sustained reduction in bleeding lasting for two
months was the selective estrogen receptor modulator (SERM) tamoxifen in users of the
levonogestrel (LNG) contraceptive implant. Based on the investigators encouraging preliminary
data of tamoxifen and ENG implant users, the investigators plan to perform additional studies
on the impact of tamoxifen on the breakthrough bleeding experience by ENG implant users.
Phase:
Phase 4
Details
Lead Sponsor:
Oregon Health and Science University
Collaborator:
Merck Women's Health Investigator Initiated Studies Program